MHRA Drug Safety Update: routine monitoring of liver function for lenalidomide (RevlimidT)

Source: MHRA Area: Evidence > Medication Safety The January issue of the MHRA's Drug Safety Update recommends the routine monitoring of hepatic function with lenalidomide (RevlimidT) following reports of suspected adverse hepatic reactions and evidence to suggest that lenalidomide may be associated with drug-induced liver injury.   In light of this evidence, healthcare professionals are given the following advice:   . Routine monitoring of liver function with the same frequency as haematological monitoring* is recommended for patients receiving lenalidomide. This is particularly important in patients with a history of, or concurrent, viral liver infection, or when lenalidomide is given at the same time as other medications known to be associated with liver injury.   . Prescribers should consider the possibility of lenalidomide-induced liver injury in patients presenting with otherwise unexplained deterioration of liver function.   . Impairment of liver function ...
Source: NeLM - Patient Safety - Category: Drugs & Pharmacology Source Type: news